Alt Stock Quote Overview of Altimmune Inc

Altimmune Inc is a biopharmaceutical company that has made significant strides in the development of novel vaccines and immunotherapies.

The company's most notable product is its COVID-19 vaccine, AdCOVID, which has shown promising results in clinical trials.

Altimmune Inc is a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol ALT.

Its market capitalization is around $120 million, giving it a relatively small market presence compared to larger biotech companies.

Altimmune's financial information reveals a complex picture. Revenue is expected to be $0 in 2025, but will jump to $469 million in 2028.

The company's dividend yield is currently 0.00%, indicating that investors are not receiving any dividend payments. However, this could change in the future as the company's financial situation improves.

The P/E ratio is expected to be 2.21 in 2027, which is a significant improvement from the negative P/E ratios in 2025 and 2026. This suggests that investors are becoming more optimistic about the company's future prospects.

Here's a summary of Altimmune's estimated revenue growth:

The company's net profit is expected to turn positive in 2028, with an estimated net profit of $262 million. This is a significant improvement from the net losses in 2025 and 2026.

Worth a look: Net Stock Quote

Estimates in USD are a crucial part of understanding a company's financial health. The average estimate for earnings per share (EPS) in 2026 is -$1.59 USD.

The number of analysts making estimates varies, but in 2025, 5 analysts were making estimates for the current quarter ending 03/31/25, with an average estimate of -$0.380 USD. This is a decrease from the previous quarter, where 9 analysts made estimates with an average of -$0.336 USD.

The average estimate for revenue in 2027 is $55 USD, with 3 analysts making estimates for the next quarter ending 06/30/25. This is a significant increase from the previous quarter, where 6 analysts made estimates with an average of $0 USD.

Here's a breakdown of the average estimates for earnings per share and revenue in USD for the next few years:

Note that the number of analysts making estimates and the average estimates themselves can fluctuate over time.

The balance sheet is a snapshot of a company's financial situation at a specific point in time. It's a crucial tool for understanding a company's financial health.

Total liabilities have fluctuated over the years, ranging from 6.44 million USD in 2018 to 21.64 million USD in 2022.

Long-term liabilities per share have been decreasing since 2019, with a significant drop from 0.30 to 0.06 in 2023.

Equity has also shown some variation, with a notable increase from 48.31 million USD in 2019 to 194.10 million USD in 2023.

The equity change percentage has been quite volatile, with a 396.21% increase in 2020 and a -6.95% decrease in 2022.

Here's a breakdown of the balance sheet total change in percentages over the years:

Altimmune's stock price history is a wild ride. The all-time high stock closing price was 701.85 on March 14, 2006.

The 52-week high and low stock prices are 14.84 and 5.28, respectively, which is 112% and 24.6% above and below the current share price. This indicates a significant fluctuation in the stock's value.

The average stock price for the last 52 weeks is 7.69. This is a relatively stable figure, considering the company's history of volatility.

Here's a breakdown of Altimmune's stock price history over the past 20 years:

This data shows the significant fluctuations in Altimmune's stock price over the years.

Altimmune's experimental drug Pemvidutide is being tested for its effectiveness in treating patients with MASH, a condition associated with metabolic dysfunction.

Results from the phase 2b IMPACT study using Pemvidutide are expected in Q2 of 2025.

The global metabolic dysfunction-associated steatohepatitis market size is expected to be a significant market for Pemvidutide, potentially providing Altimmune with a competitive edge.

Altimmune is working on announcing topline results from its obesity drug trial, which could also impact the market size of MASH treatments.